Not currently recruiting at UCLA
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at Los Angeles, California and other locations
- Dates
- study startedstudy ends around
- Principal Investigator
- by Rena D. Callahan, MD

Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Lead Scientist at UCLA
- Rena D. Callahan, MD
HS Associate Clinical Professor, Medicine
Details
- Status
- accepting new patients at some sites,
but this study is not currently recruiting here - Start Date
- Completion Date
- (estimated)
- Sponsor
- Celcuity Inc
- Links
- Sign up for this study
- ID
- NCT06757634
- Phase
- Phase 3 Breast Cancer Research Study
- Study Type
- Interventional
- Participants
- Expecting 674 study participants
- Last Updated